Centocor crosses $100 mil. quarterly sales threshold
Executive Summary
Product sales during the first quarter totaled $100.5 mil., an increase of 78%. Sales of the thrombolytic Retavase (retaplase) were up 67% to $20.4 mil. Centocor's share of sales of ReoPro (abciximab) was up 27% to $58 mil. during the quarter. Marketing partner Lilly reported that sales to end users increased 44% to $101 mil